{
  "paper_id": "7JZSQIHG",
  "title": "Relevance of CONSORT reporting criteria for research on eHealth interventions",
  "abstract": "CONSORT-EHEALTH checklist (V.1.6.1): 2011 checklist of",
  "year": 2010,
  "date": "2010-12",
  "journal": "Patient Educ Couns",
  "publication": "Patient Educ Couns",
  "doi": "10.1016/j.pec.2010.07.040",
  "keywords": [
    "experimental treatment",
    "comparator",
    "care providers",
    "centers",
    "and blinding status 1"
  ],
  "sections": [
    {
      "title": "Introduction"
    },
    {
      "title": "Background and objectives 2a",
      "text": "Scientific background and explanation of rationale 2 2b\n\nSpecific objectives or hypotheses 2"
    },
    {
      "title": "Methods"
    },
    {
      "title": "Trial design 3a",
      "text": "Description of trial design (such as parallel, factorial) including allocation ratio 2 3b\n\nImportant changes to methods after trial commencement (such as eligibility criteria), with reasons N/A Participants 4a Eligibility criteria for participants 2-3 4b\n\nSettings and locations where the data were collected\n\n3 Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 3-4 Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 4 6b Any changes to trial outcomes after the trial commenced, with reasons N/A Sample size 7a How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed 4 7b When applicable, explanation of any interim analyses and stopping guidelines 4 Randomisation: Sequence generation 8a Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group 8b Type of randomisation; details of any restriction (such as blocking and block size) 3 Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned 3 Implementation 10 Who generated the random allocation sequence, who enrolled and who assigned participants to interventions 3 Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment N/A 11b If relevant, description of the similarity of interventions 4 Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed 4 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 4 Ethics & Informed Consent X26 2 Results Participant flow (a diagram is strongly recommended) 13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center 3-4 13b For each group, losses and exclusions after randomisation, together with reasons 3-4 Recruitment 14a Dates defining the periods of recruitment and follow-up 3-4 14b Why the trial ended or was stopped [early] N/A Baseline data 15 A table showing baseline demographic and clinical characteristics for each group NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group 5 Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 3-5 Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) 6 17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 6 Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 6-8 pre-specified from exploratory Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A Discussion Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 8-9 Generalisability 21 Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial 8-9 Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group 8-9 Other information Registration 23 Registration number and name of trial registry 2 Protocol 24 Where the full trial protocol can be accessed, if available 2 Funding 25 Sources of funding and other support (such as supply of drugs), role of funders N/A Competing interests X27 9\n\n* Please view this document for an explanation of specific EHEALTH clarifications needed for each item.\n\n**CONSORT = Consolidated Standards of Reporting Trials  [10]  *** NPT = non pharmacological treatment (CONSORT extension)  [11]"
    }
  ],
  "references": [
    {
      "title": "Relevance of CONSORT reporting criteria for research on eHealth interventions",
      "authors": [
        "T Baker",
        "D Gustafson",
        "B Shaw",
        "R Hawkins",
        "S Pingree",
        "L Roberts",
        "V Strecher"
      ],
      "year": 2010,
      "doi": "10.1016/j.pec.2010.07.040"
    },
    {
      "title": "STARE-HI--Statement on reporting of evaluation studies in Health Informatics",
      "authors": [
        "J Talmon",
        "E Ammenwerth",
        "J Brender",
        "N De Keizer",
        "P Nyk\u00e4nen",
        "M Rigby"
      ],
      "year": 2008
    },
    {
      "title": "Issues in evaluating health websites in an Internet-based randomized controlled trial",
      "authors": [
        "G Eysenbach"
      ],
      "year": 2002,
      "doi": "10.2196/jmir.4.3.e17"
    },
    {
      "title": "Missing Data Approaches in eHealth Research: Simulation Study and a Tutorial for Nonmathematically Inclined Researchers",
      "authors": [
        "M Blankers",
        "Mwj Koeter",
        "G Schippers"
      ],
      "year": 2010,
      "doi": "10.2196/jmir.1448"
    },
    {
      "title": "The law of attrition",
      "authors": [
        "G Eysenbach"
      ],
      "year": 2005,
      "doi": "10.2196/jmir.7.1.e11"
    },
    {
      "title": "Establishing Guidelines for Executing and Reporting Internet Intervention Research",
      "authors": [
        "Proudfoot"
      ],
      "doi": "10.1080/16506073.2011.573807"
    },
    {
      "title": "Using the Internet to Promote Health Behavior Change: A Systematic Review and Meta-analysis of the Impact of Theoretical Basis, Use of Behavior Change Techniques, and Mode of Delivery on Efficacy",
      "authors": [
        "T Webb",
        "J Joseph",
        "L Yardley",
        "S Michie"
      ],
      "year": 2010,
      "doi": "10.2196/jmir.1376"
    },
    {
      "title": "Online Interventions for Social Marketing Health Behavior Change Campaigns: A Meta-Analysis of Psychological Architectures and Adherence Factors",
      "authors": [
        "B Cugelman",
        "M Thelwall",
        "P Dawes"
      ],
      "year": 2011,
      "doi": "10.2196/jmir.1367"
    },
    {
      "title": "Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES)",
      "authors": [
        "G Eysenbach"
      ],
      "year": 2004,
      "doi": "10.2196/jmir.6.3.e34"
    },
    {
      "title": "CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials",
      "authors": [
        "K Schulz",
        "D Altman",
        "D Moher"
      ],
      "year": 2010,
      "doi": "10.1371/journal.pmed.1000251"
    },
    {
      "title": "Extending the CONSORT Statement to randomized trials of nonpharmacologic treatment: explanation and elaboration",
      "authors": [
        "I Boutron",
        "D Moher",
        "D Altman",
        "K Schulz",
        "P Ravaud",
        "Group"
      ],
      "year": 2008,
      "doi": "10.7326/0003-4819-148-4-200802190-00008"
    }
  ],
  "num_references": 11
}
